J. Chen, B. Yu / Tetrahedron Letters 49 (2008) 1682–1685
1685
11. Schmidt, R. R. Angew. Chem., Int. Ed. Engl. 1986, 25, 212–235.
3,4,6-tri-O-acetyl-N-trichloroethylsulfuryl-a-D-glucosamino-
syl trichloroacetimidate was readily prepared. Glycosyl-
ation with this donor provided the corresponding b-
glucosaminosides stereoselectively and in excellent yields.
The TCE protection on glucosamine-N-sulfate derivatives
stayed stable under a variety of conditions for the manipu-
lation of other protecting groups, and was readily remov-
able with zinc in the presence of ammonium chloride in
methanol.
23
12. Selected data for the new compounds. Compound 5: ½aꢁD 47.3 (c 1.0,
CHCl3); 1H NMR (CDCl3, 300 MHz): d 2.07 (s, 3H), 2.08 (s, 3H),
2.14 (s, 3H), 4.01 (dd, J = 10.8, 3.3 Hz, 1H), 4.09–4.15 (br m, 2H),
4.20–4.31 (m, 1H), 4.62 (2d, J = 11.1 Hz, 2H), 5.24 (t, J = 9.6 Hz,
1H), 5.35 (t, J = 9.9 Hz, 1H), 6.55 (d, J = 3.6 Hz, 1H), 8.91 (s, 1H);
13C NMR (CDCl3, 75 MHz): d 20.4, 20.57, 20.58, 56.1, 61.2, 67.4,
69.6, 69.9, 78.2, 90.4, 93.0, 94.4, 160.0, 169.1, 170.6, 171.6. Compound
23
7b: ½aꢁD ꢀ23.7 (c 1.0, CHCl3); 1H NMR (CDCl3, 300 MHz): d 2.03 (s,
3H), 2.04 (s, 3H), 2.08 (s, 3H), 3.77 (s, 3H), 3.80–3.85 (m, 2H), 4.07–
4.16 (m, 2H), 4.28 (dd, J = 12.3, 5.1 Hz, 1H), 4.69 (s, 2H), 4.92 (d,
J = 5.4 Hz, 1H), 5.10 (t, J = 9.3 Hz, 1H), 5.22 (t, J = 9.9 Hz, 1H),
6.81–6.84 (m, 2H), 7.01–7.04 (m, 2H); 13C NMR (CDCl3, 75 MHz): d
20.5, 20.7, 20.8, 55.6, 58.7, 61.9, 68.5, 71.7, 72.6, 78.6, 93.2, 100.0,
114.6, 118.8, 150.4, 155.9, 169.5, 170.8, 171.6; ESIMS m/z 644.1
Acknowledgments
23
[M+Na]+. Compound 9: ½aꢁD ꢀ28.7 (c 1.0, CH3OH); 1H NMR
Financial support from the National Natural Science
Foundation of China (20572122 and 20621062) and the
Committee of Science and Technology of Shanghai
(06XD14026 and 04DZ19213) is gratefully acknowledged.
(CDCl3, 300 MHz): d 3.59–3.71 (br m, 3H), 3.75 (s, 3H), 3.83 (t,
J = 9.9 Hz, 1H), 3.99 (t, J = 9.3 Hz, 1H), 4.31 (dd, J = 10.2, 4.2 Hz,
1H), 4.93 (2d, J = 11.1 Hz, 2H), 5.15 (d, J = 8.1 Hz, 1H), 5.66 (s, 1H),
6.87 (d, J = 9.3 Hz, 2H), 7.10 (d, J = 8.7 Hz, 2H), 7.37–7.42 (m, 3H),
7.50–7.52 (m, 2H); 13C NMR (CD3OD, 75 MHz): d 55.6, 62.1, 66.8,
68.7, 72.2, 78.8, 82.0, 94.8, 101.6, 101.9, 115.0, 118.9, 127.0, 128.6,
129.4, 138.6, 152.0, 156.1; ESIMS m/z 583.8 [M+H]+. Compound 10:
References and notes
23
½aꢁD ꢀ8.3 (c 1.0, CHCl3); 1H NMR (CDCl3, 300 MHz): d 2.14 (s, 3H),
1. For a recent review on the heparin–protein interactions, see: Capila,
I.; Lindhardt, R. J. Angew. Chem., Int. Ed. 2002, 41, 390–412.
2. For an elaborate case study, see: Petitou, M.; van Boeckel, C. A. A.
Angew. Chem., Int. Ed. 2004, 43, 3118–3133.
3. For a recent review on the chemical synthesis of heparin oligosac-
charides, see: Poletti, L.; Lay, L. Eur. J. Org. Chem. 2003, 2999–3024.
4. Penney, C. L.; Perlin, A. Carbohydr. Res. 1981, 93, 241–246.
5. Proud, A. D.; Prodger, J. C.; Flitsch, S. L. Tetrahedron Lett. 1997, 38,
7243–7246.
6. (a) Karst, N. A.; Islam, T. F.; Linhardt, R. J. Org. Lett. 2003, 5, 4839–
4842; (b) Karst, N. A.; Islam, T. F.; Avci, F. Y.; Linhardt, R. J.
Tetrahedron Lett. 2004, 45, 6433–6437.
7. Simpson, L. S.; Widlanski, T. S. J. Am. Chem. Soc. 2006, 128, 1605–
1610.
2.60 (s, 3H), 3.68 (dd, J = 9.6, 4.5 Hz, 1H), 3.76 (s, 3H), 3.74–3.82 (m,
2H), 4.31 (dd, J = 10.5, 5.7 Hz, 1H), 4.44 (dd, J = 10.2, 7.5 Hz, 1H),
4.83 (2d, J = 10.8 Hz, 2H), 5.50 (s, 1H), 5.91 (t, J = 9.3 Hz, 1H), 6.07
(d, J = 8.1 Hz, 1H), 6.80–6.83 (m, 2H), 6.92–6.95 (m, 2H), 7.34–7.36
(m, 3H), 7.42–7.46 (m, 2H); 13C NMR (CDCl3,75 MHz): d 20.8, 20.4,
55.5, 64.9, 66.3, 68.45, 68.49, 79.4, 79.7, 92.1, 98.6, 101.6, 114.7, 119.1,
126.2, 128.2, 129.2, 136.7, 149.3, 156.1, 170.5, 170.9; ESIMS m/z 690.1
23
[M+Na]+. Compound 11: ½aꢁD ꢀ12.0 (c 1.0, CH3OH); 1H NMR
(CD3OD, 300 MHz): d 3.50–3.59 (br m, 5H), 3.69–3.74 (br m, 2H),
4.00–4.02 (br m, 5H), 4.13–4.20 (br m, 1H), 7.06–7.12 (m, 2H), 7.31–
7.37 (m, 2H); 13C NMR (CD3OD, 75 MHz): d 56.4, 62.1, 62.8, 71.9,
77.6, 78.0, 102.2, 115.7, 119.8, 153.4, 156.9; ESIMS m/z 364.1
23
[MꢀH]ꢀ. Compound 13: ½aꢁD ꢀ59.8 (c 1.0, CH3OH); 1H NMR
(CD3OD, 300 MHz): d 1.32 (s, 6H), 1.39 (s, 3H), 1.54 (s, 3H), 3.04 (t,
J = 8.7 Hz, 1H), 3.30–3.37 (br m, 3H), 3.62–3.78 (m, 3H), 3.87 (dd,
J = 15.3, 1.8 Hz, 1H), 3.97 (dd, J = 11.1, 4.5 Hz, 1H), 4.05–4.10 (br
m, 1H), 4.31–4.36 (m, 2H), 4.50 (d, J = 8.1 Hz, 1H), 4.61 (dd, J = 8.1,
2.4 Hz, 1H), 5.50 (d, J = 4.8 Hz, 1H); 13C NMR (CD3OD, 75 MHz):
d 24.8, 25.4, 26.6, 26.7, 61.9, 63.1, 69.3, 69.6, 72.1, 72.2, 72.3, 72.6,
78.2, 97.9, 103.1, 110.4, 110.7; ESIMS m/z 500.1 [MꢀH]ꢀ.
8. (a) Liu, Y.; Lien, I. F.; Ruttgaizer, S.; Dove, P.; Taylor, S. D. Org.
Lett. 2004, 6, 209–212; (b) Ingram, L. J.; Taylor, S. D. Angew. Chem.,
Int. Ed. 2006, 45, 3503–3506.
9. Myszka, H.; Bednarczyk, D.; Najder, M.; Kaca, W. Carbohydr. Res.
2003, 338, 133–141.
10. Hedayatullah, M.; Leveque, J. C.; Denivelle, L. C.R. Acad. Sci., Paris
Ser. C 1971, 273, 1444–1447.